-
Mashup Score: 4Risk for Second Primary Cancers by Type of Radiation Therapy in Older Men With Prostate Cancer - 8 month(s) ago
This cohort study evaluates whether radiotherapy type (intensity-modulated radiotherapy vs 3-dimensional conformal radiotherapy) was associated with second primary cancer risk among older men treated for prostate cancer.
Source: jamanetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 10Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma - 8 month(s) ago
Patient-reported outcomes provide an important measure of health-related quality of life and can complement efficacy and safety results. This article presents a
Source: academic.oup.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Results from #KEYNOTE564 showed that adjuvant #pembrolizumab improved disease-free survival with a manageable safety profile and preservation of quality of life in post-nephrectomy patients with renal cell carcinoma. #gucsm @DrChoueiri @tompowles1 https://t.co/kjonvZ2NXX https://t.co/jTaTe2UZS6
-
-
Mashup Score: 2
There has been increasing discussion about the sequential use of ARSIs, particularly after progression on a prior agent. However, sequential ARSI use has demonstrated limited efficacy in most patients with advanced metastatic castration-resistant prostate cancer.
Source: dailynews.ascopubs.orgCategories: Latest Headlines, Partners & KOLsTweet-
.@DrRanaMcKay of @UCSanDiego for #ASCODailyNews on when to use an ARSI followed by another ARSI in #ProstateCancer: “Sequential use should be restricted to carefully selected clinical scenarios given limited clinical efficacy.” 👉 https://t.co/S4tXpPSOaf #pcsm #GUCSM https://t.co/nt5XXUJ544
-
-
Mashup Score: 0Association of Second-Generation Antiandrogens With Cognitive and Functional Toxic Effects - 9 month(s) ago
This systematic review and meta-analysis examines the risk of toxic effects associated with second-generation antiandrogens administered to men with prostate cancer in randomized clinical trials.
Source: jamanetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Systematic review & meta-analysis shows second-generation antiandrogens utilized to treat prostate cancer increase the risk of cognitive toxicity, fatigue, & falls. https://t.co/2GjAkwGe4s #PCSM #GUCSM
-
-
Mashup Score: 3Clinical Conundrum: De-Escalating Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer - 9 month(s) ago
Treatment intensification in mHSPC leads to significant improvements in overall survival at the expense of long-term toxicity, making de-escalation strategies attractive in the right population.
Source: dailynews.ascopubs.orgCategories: Latest Headlines, Partners & KOLsTweet-
Clinical conundrum: In which circumstances do you think about de-escalating therapy in pts w/ #mHSPC? Oncology experts unpack the question in the latest #ASCODailyNews editorial. 👉 https://t.co/0Jf0OHNuBj #GUCSM #pcsm @EdmondMKwan @LouiseKostos @AzadOncology https://t.co/WGZl14gnOf
-
-
Mashup Score: 1Triplet Therapy for mHSPC: How Can We Optimize Patient Outcomes While Minimizing Treatment Toxicity? - 9 month(s) ago
Triplet therapy (androgen deprivation therapy, androgen receptor signaling inhibitor, and docetaxel) is on the verge of transforming the metastatic hormone-sensitive prostate cancer treatment landscape. But will treatment toxicity, financial burden, and heterogenous disease characteristics prevent this combination from being used in the real-world setting?
Source: dailynews.ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
An international team of physicians discuss the promise & challenges of optimizing triplet therapy for pts w #mHSPC. How can we improve pt outcomes while minimizing treatment toxicity? https://t.co/WqfRVIVYaR #ASCODailyNews #GUCSM @dr_rajwa @Albert0Briganti @DrShariat @GGandaglia https://t.co/sMRGZGqCxZ
-
-
Mashup Score: 0
Neoadjuvant dd-MVAC improves overall and disease-specific survival vs gemcitabine-cisplatin in muscle-invasive bladder cancer, a phase 3 trial suggests.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Practice-changing results from the phase 3 VESPER trial: Neoadjuvant dd-MVAC improved outcomes vs gemcitabine-cisplatin in patients with MIBC. #blcsm #ASCO23 #gucsm https://t.co/KgD4fRA78p
-
-
Mashup Score: 0
Adding talazoparib to first-line treatment with enzalutamide improves rPFS in patients with HRR-deficient mCRPC, a phase 3 trial suggests.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adding talazoparib to first-line treatment with enzalutamide improved rPFS in patients with HRR-deficient mCRPC in the phase 3 TALAPRO-2 trial. #ASCO23 #gucsm #pcsm https://t.co/Uyhrxz6cZl
-
-
Mashup Score: 0Erdafitinib Plus Cetrelimab Elicits Durable Responses in Metastatic Urothelial Carcinoma - 10 month(s) ago
Erdafitinib alone or in combination with cetrelimab has shown activity in a phase 2 trial of patients with FGFR-altered metastatic urothelial carcinoma.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Erdafitinib alone or in combination with cetrelimab showed activity in patients with FGFR-altered metastatic urothelial carcinoma in the phase 2 NORSE trial. #ASCO23 #gucsm #blcsm https://t.co/Zl6FY0Hkwk
-
-
Mashup Score: 0Immune Checkpoint Inhibitor Rechallenge of No Benefit in Advanced RCC - 10 month(s) ago
Immune checkpoint inhibitor rechallenge did not improve outcomes in patients with advanced renal cell carcinoma in the phase 3 CONTACT-03 trial.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Immune checkpoint inhibitor rechallenge did not improve outcomes in patients with advanced RCC in the phase 3 CONTACT-03 trial. #ASCO23 #gucsm #rccsm https://t.co/pr37YxiwU3
-
In this population-based study of older prostate cancer patients, IMRT for prostate cancer is not driving an increased risk of second malignancies, either solid or hematologic. https://t.co/uWLjRGs2Ke #PCSM #GUCSM